S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
NASDAQ:LYRA

Lyra Therapeutics (LYRA) Stock Forecast, Price & News

$3.88
-0.03 (-0.77%)
(As of 04:00 PM ET)
Compare
Today's Range
$3.73
$4.03
50-Day Range
$3.09
$4.80
52-Week Range
$1.86
$5.67
Volume
101,465 shs
Average Volume
186,915 shs
Market Capitalization
$192.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.67

Lyra Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
302.7% Upside
$15.67 Price Target
Short Interest
Healthy
0.85% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Lyra Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.42) to ($1.27) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

376th out of 969 stocks

Surgical & Medical Instruments Industry

48th out of 100 stocks


LYRA stock logo

About Lyra Therapeutics (NASDAQ:LYRA) Stock

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

LYRA Price History

LYRA Stock News Headlines

Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)
“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”
H.C. Wainwright Keeps Their Buy Rating on Lyra Therapeutics (LYRA)
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)
“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”
Lyra Therapeutics Inc Ordinary Shares
See More Headlines
Receive LYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LYRA Company Calendar

Last Earnings
8/08/2023
Today
10/02/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LYRA
Fax
N/A
Employees
73
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.67
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+300.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-55,280,000.00
Net Margins
-4,917.12%
Pretax Margin
-4,913.97%

Debt

Sales & Book Value

Annual Sales
$1.36 million
Book Value
$2.54 per share

Miscellaneous

Free Float
40,915,000
Market Cap
$193.74 million
Optionable
Not Optionable
Beta
-0.20
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Harlan W. Waksal M.D. (Age 70)
    Exec. Chairman
    Comp: $214.06k
  • Dr. Maria Palasis Ph.D. (Age 58)
    CEO, Pres & Director
    Comp: $865.15k
  • Dr. Richard Nieman M.D. (Age 60)
    Chief Medical Officer
    Comp: $606.7k
  • Dr. Carmichael S. Roberts Jr. (Age 55)
    Ph.D., Co-Founder
  • Mr. Jason Cavalier (Age 50)
    CFO, Treasurer & Sec.
  • Mr. Ray Knox
    VP of Operations
  • Dr. John E. Bishop Ph.D. (Age 61)
    Chief Technology Officer
  • Ms. Ellen Cavaleri
    Sr. VP of Investor Relations & Communications
  • Ms. Corinne Noyes (Age 55)
    Sr. VP of Commercial Strategy & Market Devel.
  • Ms. Vineeta Belanger Ph.D.
    Sr. VP of Clinical Affairs













LYRA Stock - Frequently Asked Questions

Should I buy or sell Lyra Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LYRA shares.
View LYRA analyst ratings
or view top-rated stocks.

What is Lyra Therapeutics' stock price forecast for 2023?

3 analysts have issued 1 year target prices for Lyra Therapeutics' shares. Their LYRA share price forecasts range from $12.00 to $20.00. On average, they expect the company's stock price to reach $15.67 in the next twelve months. This suggests a possible upside of 300.7% from the stock's current price.
View analysts price targets for LYRA
or view top-rated stocks among Wall Street analysts.

How have LYRA shares performed in 2023?

Lyra Therapeutics' stock was trading at $3.14 at the beginning of 2023. Since then, LYRA stock has increased by 24.5% and is now trading at $3.91.
View the best growth stocks for 2023 here
.

Are investors shorting Lyra Therapeutics?

Lyra Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 421,100 shares, an increase of 661.5% from the August 31st total of 55,300 shares. Based on an average daily volume of 348,200 shares, the days-to-cover ratio is currently 1.2 days.
View Lyra Therapeutics' Short Interest
.

When is Lyra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our LYRA earnings forecast
.

How were Lyra Therapeutics' earnings last quarter?

Lyra Therapeutics, Inc. (NASDAQ:LYRA) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.11. The company earned $0.46 million during the quarter, compared to the consensus estimate of $0.41 million. Lyra Therapeutics had a negative net margin of 4,917.12% and a negative trailing twelve-month return on equity of 70.42%.

What other stocks do shareholders of Lyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE), DocuSign (DOCU), Intel (INTC), OPKO Health (OPK), Valero Energy (VLO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Gilead Sciences (GILD), Micron Technology (MU) and ONEOK (OKE).

When did Lyra Therapeutics IPO?

(LYRA) raised $52 million in an initial public offering on Friday, May 1st 2020. The company issued 3,500,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair acted as the underwriters for the IPO and BTIG was co-manager.

What is Lyra Therapeutics' stock symbol?

Lyra Therapeutics trades on the NASDAQ under the ticker symbol "LYRA."

How do I buy shares of Lyra Therapeutics?

Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lyra Therapeutics' stock price today?

One share of LYRA stock can currently be purchased for approximately $3.91.

How much money does Lyra Therapeutics make?

Lyra Therapeutics (NASDAQ:LYRA) has a market capitalization of $193.74 million and generates $1.36 million in revenue each year. The company earns $-55,280,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

How can I contact Lyra Therapeutics?

Lyra Therapeutics' mailing address is 480 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.lyratherapeutics.com. The company can be reached via phone at 617-393-4600 or via email at laurence@gilmartinir.com.

This page (NASDAQ:LYRA) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -